Edition:
United States

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

1.42USD
12:26pm EST
Change (% chg)

$-0.08 (-5.00%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.55
Day's Low
$1.42
Volume
71,589
Avg. Vol
31,851
52-wk High
$2.92
52-wk Low
$1.33

Latest Key Developments (Source: Significant Developments)

Affimed reports Q3 loss per share EUR 0.18
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Affimed Nv :Affimed reports financial results for third quarter 2017.Q3 loss per share EUR 0.18.Q3 earnings per share view EUR -0.17 -- Thomson Reuters I/B/E/S.Q3 revenue eur 500,000 versus EUR 900,000.Q3 revenue view EUR 933,000 -- Thomson Reuters I/B/E/S.  Full Article

Affimed announces Q3 financial results and corporate update conference call
Monday, 30 Oct 2017 06:01am EDT 

Oct 30 (Reuters) - Affimed Nv :Affimed announces third quarter 2017 financial results and corporate update conference call.  Full Article

Affimed posts Q2 loss of EUR 0.18 per share
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Affimed Nv :Affimed reports financial results for second quarter 2017.Q2 loss per share EUR 0.18.Q2 earnings per share view EUR -0.20 -- Thomson Reuters I/B/E/S.Q2 revenue EUR 500,000 versus EUR 2.1 million.Q2 revenue view EUR 1.2 million -- Thomson Reuters I/B/E/S.Cash and cash equivalents and financial assets totaled EUR 48.9 million as of June 30, 2017.  Full Article

Affimed reports Q1 loss per share EUR 0.19
Wednesday, 17 May 2017 07:30am EDT 

May 17 (Reuters) - Affimed NV :Affimed reports financial results for first quarter 2017.Q1 loss per share eur 0.19.Q1 revenue EUR 400,000 versus EUR 1.9 million.Q1 revenue view EUR 1.5 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view eur -0.21 -- Thomson Reuters I/B/E/S.Affimed NV - cash and cash equivalents and financial assets totaled eur 53.7 million as of march 31, 2017 compared to eur 44.9 million as of december 31, 2016.  Full Article

Affimed reports Q4 loss per share EUR 0.16
Thursday, 30 Mar 2017 07:31am EDT 

Affimed NV : Affimed reports financial results for fourth quarter and year end 2016 . Q4 loss per share eur 0.16 . Q4 earnings per share view EUR -0.29 -- Thomson Reuters I/B/E/S . Q4 revenue EUR 1.4 million versus EUR 1.7 million . Q4 revenue view EUR 1.1 million -- Thomson Reuters I/B/E/S .Affimed NV - including proceeds from offering in January and February 2017, company's operations are expected to be funded at least until end of 2018.  Full Article

Affimed announces closing of public offering of common stock
Wednesday, 25 Jan 2017 04:01pm EST 

Affimed Nv - :Affimed announces closing of public offering of common stock.  Full Article

Affimed says public offering of 10 mln common shares priced at $1.80/shr
Friday, 20 Jan 2017 09:13am EST 

Affimed NV : Affimed announces pricing of public offering of common stock .Says public offering of 10 million common shares priced at $1.80 per share.  Full Article

Affimed announces proposed public offering of common stock
Thursday, 19 Jan 2017 04:04pm EST 

Affimed NV :Affimed announces proposed public offering of common stock.  Full Article

Affimed Q2 loss per share EUR 0.24
Wednesday, 10 Aug 2016 07:30am EDT 

Affimed Nv : Affimed reports financial results for second quarter 2016 and provides corporate update . Q2 earnings per share view eur -0.20 -- Thomson Reuters I/B/E/S . Q2 loss per share eur 0.24 .Q2 revenue eur 2.1 million versus i/b/e/s view eur 1.9 million.  Full Article

Affimed Q1 loss per share Eur 0.25
Wednesday, 18 May 2016 07:30am EDT 

Affimed NV : Affimed reports financial results for first quarter 2016 . Q1 loss per share eur 0.25 . Q1 revenue eur 1.9 million versus i/b/e/s view eur 1.9 million .Q1 earnings per share view eur -0.17 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash